期刊文献+

嗜麦芽窄食单胞菌对氟喹诺酮类抗菌药的分子耐药机制研究 被引量:2

Investigating the Fluoroquinolone Molecular Resistant Mechanism of Stenotrophomonas maltophilia
暂未订购
导出
摘要 目的研究嗜麦芽窄食单胞菌DNA解旋酶和拓谱异构酶的突变与氟喹诺酮类药物(FQNS)的耐药关系,为新药开发提供实验依据。方法选择对环丙沙星最低抑菌浓度(MIC)≥2mg/L且主动外排表型机制阴性的菌株,对其gyrA和parE的喹诺酮决定区域基因分别进行PCR扩增,纯化后直接测序。结果嗜麦芽窄食单胞菌在DNA解旋酶最常见的83位和87位没有突变,同时在GyrA的整个喹诺酮耐药决定区域(QRDRs)没有氨基酸的改变,并且其83位是Gln而不是其它革兰阴性菌常见的Ser或Thr。5株菌中的parE各有1株菌在402和432突变,但是该突变与FQNS耐药不相关,未观察到Valdezate研究中的1/2菌株的parE突变频率高且主要集中在437、465、477和485位的现象。结论嗜麦芽窄食单胞菌对FQNS耐药与主动外排泵有关,可能与外膜的通透性降低有关,但与DNA解旋酶和拓谱异构酶的靶位点改变关系尚不明确,需进一步研究。 Objective To research DNA gyrase and topoisomerase Ⅳ quinolone reslstance-determlnlng regions (QRDRs) in Stenotrophomonas maltophilia clinical isolates with different resistant levels of quinolone susceptibility. Methods We selected five strains for which the MIC of ciprofloxacin were higher than 2 mg/L and were negative for efflux mechanism ; then we amplified their QRDRs of gyrA and parE, purified the fragment, and analyzed the nucleotide sequences. Results In Stenotrophomonas maltophilia DNA gyrA, the changes at positions 83 and 87 commonly involved in quinolones resistance in gram-negatlve bacteria were absent, and there was Gln but not Ser or Thr. Of the five strains, one strain showed a Pare amino acid change in position 402, the other was in position 432, but the mutations were not associated with FQNS resistance. Conclusion FQNS resistance in Stenotrophomonas maltophilia is related to active efflux pump and may be correlated with a low level of permeability. But it is not clear whether the resistance is related to the mutants in DNA gyrase and topoisomerase Ⅳ.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2006年第2期266-269,共4页 Journal of Sichuan University(Medical Sciences)
关键词 嗜麦芽窄食单胞菌 氟喹诺酮类抗菌药物 GYRA基因 parE基因 Stenotrophomonas maltophilia Fluoroquinolones gyrA parE
  • 相关文献

参考文献11

  • 1Vartivarian S, Anaissie E, Bodey G, etal. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobialagents: implications for therapy. Antimicrob Agents Chemother,1994;38(3):624-627.
  • 2赖福才,白英明,魏东,耿穗娜.134株嗜麦芽寡养单胞菌对12种抗菌药耐药性的测定[J].中国抗生素杂志,2002,27(4):249-250. 被引量:16
  • 3Weiss K, Restieri C, Carolis ED, et al. Comparative activity of new quinolones against326 clinical isolates of Stenotrophomonas maltophilia. J AntimicrobChemother,2000;45(2):363-365.
  • 4陶传敏,李小春,吕晓菊,李萍,俞汝佳,高燕渝,陈慧莉.氟喹诺酮类药物对嗜麦芽寡养单胞菌的抗菌活性及羰基氰氯苯腙对其的影响[J].中国抗生素杂志,2004,29(8):469-472. 被引量:6
  • 5Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis,2001;7(2):337-341.
  • 6Martinez-Martinez L, Pascual A, Jacoby GA. Quninolone resistance from a transferableplasmid. Lancet,1998;351(3):797-799.
  • 7Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonasmaltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother,2000;44(1):287-293.
  • 8Lecso-Bonet M, Pierre J, Sarkis-Karam S, et al. Susceptibility of Xanthomonasmaltophilia to six quinolones and study of outer membrane proteins in resistant mutantsselected in vitro. Antimicrob Agents Chemother,1992,36(3):669-671.
  • 9Hooper DC. Bacterial topiosomerases, anti-topoisomerases, and anti-topoisomerasesresistance. Clin Infect Dis,1998;27(suppl):S54-S63.
  • 10Valdezate S, Vindel A, Echeita A, et al. Topiosomerase Ⅱ and Ⅳ quinoloneresistance-determining regions in Stenotrophomonas maltophilia clinical isolates withdifferent levels of quinolone susceptibility. Antimicrob Agents Chemother,2002;46(3):665-671.

二级参考文献12

  • 1National Committee for Clinical Laboratory Standard.Performance standards for antimicrobial susceptibility testing[S].Twelfth informational supplement,2002,22:90
  • 2Valdezate S,Vindel A,Echeita A,et al.TopiosomeraseⅡ and Ⅳ quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility [J].Antimicrob Agents Chemother ,2002,46:665
  • 3Denton M,Kerr K G.Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia[J].Clin Microbiol Rev,1998,11(1):57
  • 4Betriu C,Sanchez A,Palau L,et al.Antibiotic resistance surveillance of Stenotrophomonas maltophilia,1993-1999[J].J Antimicrob Chemother,2001,48:152
  • 5Weiss K,Restieri C,Carolis E D,et al.Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia [J].J Antimicrob Chemother,2000,45:363
  • 6Muder R R,Harris A P,Muller S,et al.Bacteremia due to Stenotrophomonas (Xanthomonas ) maltophilia :a prospective multicenter study of 91 episodes [J].Clin Infect Dis,1996,22 (3):508
  • 7Ribera A,Jurado A,Ruiz J,et al.In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine [J].Diag Microbiol Infect Dis,2002,42:123
  • 8Lomovskaya O,Warren M S,Lee A,et al.Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa:novel agents for combination therapy [J].Antimicrob Agents Chemother,2001,45:105
  • 9National Commuittee for Clinical Laboratory Standards.Performance Standards for Antimicrobial Disk SuceptibilityTestings pennsylvania-sixth [S]. NCCLS 1997
  • 10Palleroni N J, Bradbury J F. Stenotrophomonas, a newbacterial genus for Xanthomonas maltophilia ( Hugh 1989 )swings et al. 1983 [J]. Int J Syst Bacteriol,1993 ;43:606

共引文献20

同被引文献13

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部